Ranbaxy Laboratories on Nov. 21, 2007 announced that the company received approval in Canada to manufacture and market tamsulosin hydrochloride capsules 0.4 mg from Health Canada, Therapeutic Products Directorate (TPD).
This product has proven to be bio-equivalent to flomax capsules which is indicated for the treatment of Benign Prostatic Hyperplasia (BPH). The total market for both generic and brand tamsulosin hydrochloride capsules in Canada is CAD 22 million. This is the fourth product that the company has launched in 2007.
Ranbaxy Pharmaceuticals-Canada Inc. (RPCI) based in Mississauga, Ontario, Canada, is a wholly owned subsidiary of the Company. RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.
Shares of the company declined Rs 15.25 , or 3.68% to settle at Rs 398.60. The total volume of shares traded was 196,795 at the BSE.(Wednesday).
No comments:
Post a Comment